- Research article
- Open Access
Characterisation of a natural variant of the γ-butyrolactone signalling receptor
BMC Research Notes volume 5, Article number: 379 (2012)
The control of antibiotic production in Streptomyces coelicolor A3(2) involves complicated regulatory networks with multiple regulators controlling the expression of antibiotic biosynthetic pathways. One such regulatory network is that of the γ-butyrolactones, the so-called S. coelicolor butanolide (SCB) system. The γ-butyrolactones in this system serve as signalling molecules and bind to the receptor protein ScbR, releasing the repression of its target genes. The resulting expression changes affect the production of the two pigmented antibiotics Act and Red, as well as the transcription of the cpk antibiotic biosynthesis gene cluster and the synthesis of the γ-butyrolactones themselves.
We identified a natural variant of ScbR in S. coelicolor (ScbRM600) that differs from ScbR in the genome-sequenced strain M145 (ScbRM145) by a single amino acid change, R120S. ScbRM600 is impaired in its DNA binding ability and alters the expression of the pathway-specific regulatory genes of the red and cpk antibiotic biosynthesis gene clusters. Also, expression of the γ-butyrolactone biosynthesis gene scbA and production of the signalling molecules is slightly reduced.
The γ-butyrolactone receptor, ScbR, plays a key role in the SCB regulatory cascade and in determining the onset of the expression of the antibiotic regulatory genes.
Streptomycetes show a complex morphological differentiation and produce a vast variety of secondary metabolites with great value in the pharmaceutical, chemical and agricultural industries [1, 2]. The genome sequence of the model streptomycete Streptomyces coelicolor A3(2) strain M145, has been determined and is publicly available . S. coelicolor A3(2) strains M145 and M600 are two of many strains independently derived from S. coelicolor A3(2). Both are prototrophic plasmid-free derivatives, but M145 was derived using both mutagenesis and recombination while creation of M600 did not involve any mutagenesis . Genetically, M600 differs from M145 in that it possesses long terminal inverted repeats (TIRs) at both ends of the chromosome, resulting in the duplication of 1005 genes compared to M145. This does not, however, appear to significantly affect total expression of the duplicated genes, since highly similar transcript levels could be observed when comparing the two strains .
In several Streptomyces species, small autoregulatory molecules called γ-butyrolactones are involved in controlling the onset of secondary metabolite production and morphological differentiation (reviewed in ). There are numerous diverse and complex regulatory systems involving γ-butyrolactones with the signalling cascade for A-factor in S. griseus being the best studied [6, 7]. In S. coelicolor, γ-butyrolactones stimulating the production of Act and Red have been identified , together with the genes involved in γ-butyrolactone synthesis (scbA) and γ-butyrolactone binding (scbR). ScbR regulates transcription of both scbA and itself by binding to the divergent promoter region controlling both genes, and the γ-butyrolactone SCB1 inhibits this binding . The regulatory influence of ScbR has been characterised by DNA microarray analysis, and a role in directly regulating a cryptic Type I polyketide biosynthetic gene cluster (cpk cluster) by binding to the promoter of its pathway-specific regulator cpkO was identified [10, 11]. We recently reported two metabolites derived from the hitherto orphan cpk biosynthetic pathway, the yellow pigment yCPK and an antibiotic compound, abCPK . ScbR does not, however, bind to the promoter regions of the pathway-specific regulatory genes for Act and Red synthesis , and it appears that SCB1 and scbAR do not regulate the production of these antibiotics directly. Nevertheless, an M145ΔscbR mutant (M752) is delayed in the production of Act and Red .
ScbR is a member of the TetR protein family , in which the Streptomyces γ-butyrolactone receptors show significant similarity to each other (30–40 % amino acid sequence identity). The crystal structure of a ScbR paralogue in S. coelicolor, CprB, has been determined and is assumed to generally represent the structure of γ-butyrolactone receptors . Active as homodimers, members of the TetR family bind to highly specific DNA binding sites in the promoter region of their target genes and typically repress their transcription. The regulatory region of the dimeric regulator contains one independent ligand binding pocket in each subunit. One γ-butyrolactone receptor thus binds two ligand molecules. Binding of γ-butyrolactones causes conformational changes and DNA binding is relieved .
In this study, the S. coelicolor γ-butyrolactone receptor ScbR in strain M600 (ScbR M600) was found to differ from that in the sequenced strain M145 (ScbRM145) by a single amino acid change. The effect of the M600-type protein on the production of pigmented antibiotics Act Red, and the yellow compound, yCPK, as well as the γ-butyrolactones was assessed in vivo. In addition, the influence of SCBR M600 on the expression of genes involved in the butanolide system and secondary metabolism was evaluated by quantitative real time PCR. The effect onDNA and/or γ-butyrolactone binding ability of ScbR due to the amino acid substitution was also investigated in vivo and in vitro. Sequence analysis was used to determine the prevalence of the two forms of ScbR among strains of S. coelicolor and S. lividans. The ScbRM600 variant is present in only two, independent strains of S. coelicolor and its decreased DNA binding activity results in a delay in the transcription of the antibiotic regulatory genes.
Two forms of the γ-butyrolactone receptor ScbR in strains of S. coelicolor
2D gel-based proteomic analysis of transition phase liquid cultures from S. coelicolor strain M145 identified ScbR at a position consistent with its theoretical molecular weight and isoelectric point (spot 1 in Figure 1A). However, in an extensive analysis of strain M600 grown under the same conditions ScbR was never detected (data not shown). In an analysis of protein extracts prepared from spores of M600, ScbR was detected (spot 2 in Figure 1B) but at coordinates corresponding to a significantly more acidic isoelectric point compared to that observed in M145. This difference was confirmed by performing a separation of an equal mixture of the M600 spore extract and the M145 transition phase mycelial extract (Figure 1C), and indicates the occurrence of a modified form of ScbR in S. coelicolor strain M600.
ScbRM600 from S. coelicolor M600 carries a single amino acid change, R120S, compared to ScbRM145 from strain M145
To identify the M600 ScbR modification, the chymotryptic peptides detected for the ScbR proteins in M145 spot 1 and M600 spot 2 in Figure 1 were compared (Figure 2A,B,C, Additional file 1). Peptides corresponding to all the ScbR amino acid sequence except RRWHETLL and FHFQSKEELAL (indicated by black bars in Figure 3), were detected in the ScbR spot from M600 (Additional file 1). Peptides containing tryptophan can produce up to four peptide peaks in MALDI-TOF analysis due to two successive oxidations of the tryptophan residue (i.e. parent mass +16.0 Da and +32.0 Da), followed by spontaneous deformylation to kyneurenine (parent mass +4.0 Da) , and peaks at 1126.62 Da and 1142.62 Da in the data for the M145 spot correspond to the oxidised forms of the parent ion detected at 1110.62 Da. Interestingly, these three peptides are absent in the peptide mass fingerprint for the M600 ScbR spot, but three new peptide peaks apparently corresponding to a tryptophan-containing peptide can be detected at 1041.48 Da, 1045.49 Da (parent +4.0 Da), and 1073.48 Da (parent +32.0 Da; Figure 2B,C). ScbR contains only one tryptophan residue, and the data therefore indicate that in M600 spot 2 ScbR has been modified on the RRWHETLL peptide resulting in a surprising mass loss of 69.09 Da (and an acidic shift in the isoelectric point value of the protein). This data correspond to the replacement of an arginine residue with a serine (69.069 Da). Analysis of the parent peptide ion at 1041.48 Da using Q-TOF mass spectrometry confirmed the sequence of this peptide as RSWHETLL (data not shown). This has also subsequently been verified via sequencing of the scbR gene in strain M600 (see below). The M600-type protein (ScbRM600) therefore contains a single amino acid change (R120S) compared to the M145-type protein (ScbRM145) (Figure 3).
ScbRM145 is the predominant form in S. coelicolor
To survey the distribution of the dimorphism identified in ScbR, part of the scbR coding region of 16 S. coelicolor strains was amplified by PCR using primers ScbRrt1 and ScbRrt2 and the sequence was determined. In addition, to confirm the scbR sequence in S. coelicolor M600 and S. lividans 1326, the entire scbR coding sequence and promoter region was amplified using primers ScbR2 and ETS10 (all primers used are listed in Additional file 2).ThescbR in M600, a single base pair change, c358a, was identified, confirming the amino acid mutation R120S observed in the proteomics analysis. The same mutation was also found in S. coelicolor strain A(3)2 N2, but was absent in the other 14 S. coelicolor strains tested, which all possessed the M145 genotype (Table 1). No other variants of scbR were observed in the strains tested. The scbR homologue in S. lividans differs from scbRM145 only by two silent point mutations, g402a and g582t. Thus, the S. lividans ScbR amino acid sequence is identical to that of ScbRM145. A multi-sequence alignment of the ScbR homologues are shown in Additional file 3. The scbR promoter regions from 251 bp upstream of scbR, covering the ScbR binding sites of the intergenic region between divergently transcribed scbA and scbR, are identical in S. coelicolor strains M145, M600 and also in the scbR homologue of S. lividans 1326 (data not shown). Our sequencing data were confirmed by the publicly available genome sequence of S. lividans (http://www.broadinstitute.org/annotation/genome/streptomyces_group/Regions.html).
In vivo analysis of the scbRM600 point mutation in a M145 background
Production of pigmented antibiotics in strains M145 and M600 differ, with M600 being notably delayed in the onset of Act and Red biosynthesis, and this is comparable to the phenotypic change observed in strain M145 following deletion of scbR. To determine whether the M600 phenotype may be attributed to the point mutation observed in scbRM600, a M145 ScbR deletion mutant was genetically complemented with constructs expressing either scbRM145 or scbRM600 under the native scbR promoter.
Plasmids pTE212 and pTE214 carrying scbRM600 and scbRM145, respectively, were used to replace the mutated scbRM145 locus in the M145ΔscbRM145 in-frame deletion mutant strain M752  to give strains LW33 and LW34. LW33 therefore encodes ScbRM600 in the M145 genetic background, and LW34 is the congenic control strain expressing ScbRM145. Correct construction of the strains was verified using PCR and Southern analysis (Figure 4A,B). Sequence analysis revealed a silent point mutation, c636t (leading to an “act” triplet instead of “acc”, both resulting in Thr), in scbRM145 of strain LW34 (pTE214). Besides this mutation, strains LW33 and LW34 only differ by c358a in scbR.
Strains LW33 and LW34 were grown in liquid SMM. Samples for RNA and protein isolation, as well as for γ-butyrolactone and antibiotic analysis, were collected at different phases of growth (Table 2).
Antibiotic production in S. coelicolor LW34 and LW33 is comparable
No difference could be determined for Act production. This was consistent between two independent growth experiments (Table 2). For Red, production increased 2-fold in LW33 for GC 2 but the increase was not seen in GC 1 (Table 2).
We recently identified a yellow pigment (yCPK) and an antibiotic compound (abCPK) as metabolites of the hitherto orphan cpk gene cluster  that may be the primary target of the S. coelicolor butanolide system. Therefore, in addition to Act and Red, we compared the production of the yellow compound in LW33 and LW34 grown on solid Difco Nutrient agar supplemented with glutamate where yCPK was found to be produced in high yields by the parental strain M145 . The two tested strains showed no obvious difference in the production of all three pigmented secondary metabolites during ten days of growth (Figure 5). From all these data there seems to be no significant difference in antibiotic production between LW33 and LW34 under the conditions tested, demonstrating that the difference in ScbR isoform does not explain the phenotypic difference of M145 and M600.
γ-butyrolactone production is slightly delayed in LW33
γ-butyrolactone production of S. coelicolor strains LW34 and LW33 was determined using a kanamycin bioassay  at different phases of growth (Table 2, GC 2) corresponding to the sampling time points in the transcription analysis. Kanamycin resistance of a Streptomyces indicator strain is induced by the presence of γ-butyrolactones in extracts from the tested strains, and the extent of growth of the indicator strain on media containing kanamycin reflects the amount of γ-butyrolactones produced . Extracts from stationary phase cultures of LW33 and LW34 produced similar halos of growth, indicating the presence of similar levels of γ-butyrolactones. Slightly higher levels were detected withmid and late transition phase samples in strain LW34 (Figure 6). This would indicate that ScbRM600 in strain LW33 leads to a minor reduction and delay in γ-butyrolactone production compared to LW34, and is consistent with the delay in scbA transcription observed in LW33 as shown below (Figure 7).
Expression of scbR, scbA, redD and cpkO is altered in strain LW33 containing the mutant ScbRM600
Quantitative real time PCR (qRT-PCR) was used to measure the expression levels of the pathway-specific regulators of the act (actII-ORF4), red (redD) and the cpk (cpkO) antibiotic biosynthesis gene clusters, and of scbA and scbR of the S. coelicolor butanolide system in the presence of the two forms of ScbR (Figure 7). Compared to the control strain LW34, redD expression was 2.5-fold lower at mid transition phase (mT) in LW33 harbouring the ScbRM600. RedD expression did not change dramatically from mid transition to late transition phase in LW33, while in LW34, the expression dramatically decreased. This resulted in a >2-fold higherredD expression in LW33 compared to LW34 at late transition phase. For GC 2, The onset of actII-ORF4 transcription was delayed in LW33 but this was not observed in GC 1. Expression of cpkO was only transcribed in late transition phase (lT), and thus later than in LW34. Also, the onset of scbA transcription was delayed in LW33 and shifted from mid to late transition. Also with scbR, maximum expression was reached only at late transition phase in LW33 compared to mid transition phase in LW34 (Figure 7 and Additional file 4AB).
ScbRM600from Streptomyces shows reduced ability to bind to the scbR promoter sequence
Cell-free extracts (CE) of LW34 (scbRM145) and LW33 (scbRM600) were prepared from samples taken at different phases of growth (Table 2) corresponding to the sampling time points in the transcription analysis. DNA binding ability was determined in gel retardation assays using a digoxygenin-labelled scbR promoter fragment containing the ScbR binding site upstream of its own promoter  and freshly prepared protein extracts (Figure 8A; shown for GC 1). Equivalent amounts of total protein used for the gel retardation analysis were also analysed by Western hybridization using an antibody to ScbR to determine the relative abundance of ScbR in the extracts (Figure 8B). Extracts from LW34 from late transition and stationary phase completely shifted the operator DNA in the binding assay (Figure 8A). This is consistent with the appearance of ScbR as detected by Western blotting (Figure 8B). In contrast, all LW33 extracts failed to produce a full shift. Even in the presence of a higher amount of ScbRM600 compared to ScbRM145 (LW33 in stationary and LW34 in transition phase, respectively; Figure 8B) the observed shift of ScbRM600 was weaker, suggesting that the DNA binding ability of the mutant protein in LW33 is reduced. The same results were obtained with GC 2 (data not shown).
In vitro analysis using freshly prepared protein expressed in E. coli indicates that the DNA and γ-butyrolactone binding abilities of ScbRM145 and ScbRM600 are comparable
In vivo analysis in this study indicated that expression of mutant ScbRM600 in S. coelicolor leads to altered patterns of expression of the pathway-specific regulatory genes for Red (redD) and CPK (cpkO), the scbA and scbR genes known to be controlled by ScbR in response to altered butyrolactone concentrations, and to a decreased ScbRM600 DNA binding affinity. To investigate in more detail the effect that the point mutation may have on the ability to bind both butyrolactones and its cognate DNA operator sequence, ScbRM145 and ScbRM600 were overexpressed in E. coli. Freshly prepared E. coli CE containing equal amounts (Methods; Figure 9B) of the two forms of ScbR showed comparable DNA binding abilities in gel retardation analysis (Figure 10, lanes 3 and 7, and Figure 11A, lanes 2 and 6, respectively).
Addition of low (8 ng; Figure 10, lanes 5 and 9) and high (63 ng; Figure 10, lanes 4 and 8) amounts of the cognate γ-butyrolactone ligand SCB1 led to a partial and a complete loss of DNA binding, respectively, with both ScbRM145 and ScbRM600. Therefore, under the conditions tested, the γ-butyrolactone binding affinity of the two forms of ScbR expressed in E. coli were comparable.
DNA binding ability of ScbRM600 expressed in E. coli is unstable
In gel retardation analysis using E. coli CE supplemented with 4 % (v/v) glycerol, DNA binding of the mutated ScbRM600 was reduced when stored at −20 °C for several days or weeks (data not shown). To further analyse this difference, fresh CE without glycerol was frozen and thawed up to three times at −20 °C and 37 °C, respectively, and the DNA binding affinity was tested by gel retardation analysis. To ensure equal amounts of protein for both ScbRM145 and ScbRM600, total protein concentrations of the CE were measured, and the abundance of ScbR present was confirmed by Western analysis (Figure 11B). Both proteins were active in freshly prepared and analysed CE (Figure 11A, lanes 2 and 6), but freezing and thawing of the proteins lead to a decrease (lane 7 and 8) and eventually to the loss (lane 9) of DNA binding with the mutant ScbRM600. Native ScbRM145 was not affected by the treatment (lanes 3 to 5). Western analysis indicated that freezing and thawing had no effect on the amount of protein detected (Figure 11B) indicating that the loss of DNA binding ability was not due to protein degradation. This suggests that compared to ScbRM145, the DNA binding ability of ScbRM600 is significantly less stable. This is also supported by the decrease in DNA binding affinity observed with the mutant protein, but not with ScbRM145, in the presence of methanol (Figure 10, lanes 6 and 10). This instability of ScbRM600 DNA binding activity was also seen from crude extracts obtained from Streptomyces (data not shown).
A variant form of the γ-butyrolactone receptor ScbR in S. coelicolor
In addition to ScbR from the sequenced strain M145 (ScbRM145), a natural variant of the protein, ScbR/R120S (ScbRM600), was found in strain M600 (this study). The underlying point mutation in the scbR gene, c358a, was also found in strain A3(2) N2, another S. coelicolor A3(2) derivative independent from both M145 and M600 . All 14 further strains tested showed the M145 genotype, including S. coelicolor W3443, the proposed progenitor of all strains described , and scbRM600 is thus regarded as a mutant variant. When mapping the known instances of this variant onto the lineage of S. coelicolor described by Kao and co-workers , our results indicate that the point mutation c358a occurred on two independent occasions, in strains M600 and A3(2) N2, perhaps indicating a selective pressure or an evolutionary relevance for this change under certain conditions.
The amino acid change in ScbRM600 impairs DNA binding in S. coelicolor
Compared to ScbRM145, DNA binding was reduced with ScbRM600 (from S. coelicolor LW34 and LW33, respectively; Figure 8). This difference is surprising since the functional localization of the altered amino acid 120 does not suggest an effect of the mutation in scbRM600 on the DNA binding domain of the protein. Furthermore, Horinouchi and co-workers described the helix-turn-helix motifs of mutant ArpA/W119A as still able to bind DNA . However, in the ArpA study the intensity of the shifted band observed in the absence of A-factor was noticeably weaker for the mutated ArpA/W119A than for the wild type ArpA . This also implies a reduced DNA binding affinity of ArpA/W119A, and thus suggests an effect of the amino acid change W119A in ArpA similar to that observed with ScbRM600 in this study. It is interesting to note that both variants of ScbR expressed in E.coli did not have any difference in DNA binding activity. This may suggest another component in S. coelicolor is responsible for the loss of the DNA binding activity of ScbR.
The mutation in ScbRM600 has no detectable effect on γ-butyrolactone binding
The crystal structure of a ScbR paralogue in S. coelicolor, CprB, is regarded as representative for γ-butyrolactone receptors in streptomycetes. Functional domains for dimerization, DNA binding by helix-turn-helix motifs, and γ-butyrolactone binding have been proposed. DNA binding of CprB was shown experimentally , but a putative cognate γ-butyrolactone ligand has yet to be identified . From the CprB amino acid sequence, amino acid 120 in ScbR is proposed to form part of a central α-helix (α7) in the regulatory region (Figure 3). The adjacent tryptophan residue W121 is predicted to be directly involved in forming the γ-butyrolactone binding pocket and is highly conserved among Streptomyces γ-butyrolactone receptors . Mutation of the corresponding W119 in the A-factor receptor protein ArpA, a ScbR homologue in S. griseus, abolished γ-butyrolactone binding . It therefore seems reasonable to suggest that a change in the amino acid residue 120 adjacent to the crucial W121 in ScbR, from a large (174 Da) basic arginine to a small (105 Da) neutral serine, could affect ligand binding affinity.
However, no difference in ligand binding was observed between ScbRM145 and ScbRM600 (Figure 10), and it is interesting to note that ScbR amino acid 120 is not conserved among γ-butyrolactone receptor proteins. The corresponding residues in other ScbR homologues consist of members of all classes of amino acids and of hugely differing sizes (e.g., aspartate (acidic, 133 Da) in ArpA (S. griseus); arginine (basic, 174 Da) in ScbRM145; asparagine (hydrophilic, 132 Da) in FarA (S. lavendulae); alanine (hydrophobic, 89 Da) in SpbR (S. pristinaespiralis)), all adjacent to the conserved tryptophan residue . The high level of variability at this position suggests residue 120 does not in fact play a significant role in γ-butyrolactone binding.
ScbRM600 leads to altered gene expression and has some affects on γ-butyrolactone production
Expression of scbA is delayed in LW33 (Figure 7). This could be a direct effect of the impaired DNA binding ability of ScbRM600 since ScbR was previously shown to be necessary for scbA expression . Consistently, late expression of the γ-butyrolactone synthase gene coincides with a slight delay in the production of the small signalling molecules in LW33 (Figure 6).
Also scbR expression is somewhat delayed at similar transcription levels in the presence of the M600-type protein, but not as clearly as with scbA (Figure 7). This is at first glance surprising, since a reduction in DNA binding of the auto-repressor might be expected to result in a higher or early expression of scbRM600. However, also in Western analysis no increase in the amount of ScbRM600 in LW33 was observed (Figure 8B). γ-butyrolactones abolish the DNA binding of ScbR and are active in nM concentrations (Figure 10) . The small reduction in γ-butyrolactone production observed in LW33 (Figure 6) may promote binding of ScbRM600 to its target sites in vivo, counteracting the impaired binding ability of the mutant protein.
In LW33, expression of the pathway-specific regulator genes for the red and the cpk antibiotic biosynthesis gene clusters was delayed compared to that in LW34 (Figure 7 and Additional file 4AB). However expression of scbR scbA redD cpkO and actII-orf4 has been shown to be highly similar in M145 and M600 in an extensive genome-wide study by Weaver and co-workers . Despite these differences, antibiotic production was similar in the LW33 and LW34. Regulation of production of these antibiotics is complex and known to be affected by many additional factors .The cpk gene cluster, for example, was shown to be also regulated by the RapA1/A2 two-component system  and the global regulator DasR . It appears that the changes in expression of the regulatory genes observed here are over-ridden by other control mechanisms and so do not result in any observable change in the antibiotic phenotype. Furthermore, production of other, known and unknown, secondary metabolites in S. coelicolor might impair the synthesis of Act, Red and yCPK, e.g. by competition for common precursors from primary metabolism. Further experiments will be needed to reveal the detailed effects of the mutation in ScbRM600 on the delicately balanced butanolide system in S. coelicolor.
Despite the somewhat impaired DNA binding ability of the mutant ScbRM600, our result show that strain LW33 clearly differs from a M145ΔscbR in-frame deletion mutant (M752). In comparison to M145, the latter strain is delayed in Red production, transcribes scbR early, and expresses cpkO early and constitutively [9, 10]. Evidently, the single R120S amino acid change has a different impact on the S. coelicolor butanolide system and related secondary metabolites when compared to a complete deletion. The antibiotic production in M600 also resembles that of the M145ΔscbR in-frame deletion mutant (M752) where all antibiotics are produced later than M145. We have shown that the cause of this antibiotic production phenotype is not due to the point mutation in ScbR alone.
Structural effect of amino acid change R120S on the DNA binding domain of ScbRM600
DNA binding of ScbRM600 was impaired in both the natural producer S. coelicolor and, after harsh low-temperature treatment, in E. coli CE. The decreased binding ability is therefore most probably not related to specific properties of the S. coelicolor cellular background, e.g. a hypothetical “deactivation” mechanism of the transcriptional regulator ScbR, and it is more likely that the amino acid change is causing a structural change affecting the DNA binding domain. This is also supported by the fact that a loss of ScbRM600 DNA binding could be induced by freezing and thawing of the protein (Figure 11A), and the observation that this loss was prevented by the addition of 43 % (v/v) of glycerol (data not shown). However, modelling of both ScbR variants based on the crystal structure of the ScbR paralogue CprB  does not reveal an obvious destabilizing effect of the mutation R120S in ScbRM600 (data not shown; Dirk Linke, personal communication). Also, protein aggregation, specifically of the mutated ScbRM600, could cause these effects, whereas Western analysis data shown in Figure 8B and Figure 11B clearly exclude degradation of the protein as an explanation for our observations. Prediction of enzymatic cleavage using the ExPASy Peptide Cutter (Swiss Institute of Bioinformatics (SIB)) (http://expasy.org/tools/peptidecutter/) only revealed an additional cleavage site for pepsin at pH1.3 (and not pH > 2) in ScbRM600, and the loss of one site each for Arg-C proteinase, clostripain and trypsin (data not shown).
The mutation in ScbRM600 is not responsible for the absence of the protein in vegetative mycelium of strain M600
To our surprise and in contrast to M145, ScbRM600 was absent during vegetative growth in M600 as shown by 2D gel (Figure 1) and Western analysis (data not shown). However, ScbRM600 was present in vegetative mycelium of S. coelicolor LW33 harbouring scbRM600 in an M145 genetic background. The amounts were comparable to ScbRM145 in the control strain LW34 (Figure 8B) and in M145 (data not shown). This suggests that it is the M600 genetic background, and not the amino acid change in ScbRM600, that is the reason for the absence of ScbR during vegetative growth of M600. Whether the altered properties of ScbRM600 are an adaptation to its synthesis in the spores of S. coelicolor M600 and/or to a putative modified function of the regulator which again might indicate evolutionary relevance remains to be determined. Detailed knowledge of the butanolide regulatory system in S. coelicolor might allow rational construction of strains with improved timing and levels of antibiotic production.
Among at least five paralogues in S. coelicolor (CprA, CprB, SCO6323, ScbR and ScbR2), ScbR is the only γ-butyrolactone receptor experimentally shown to bind a cognate signalling molecule. Recently, SCO0608 (SlbR) was shown to also bind to butyrolactones with less specificity compared to ScbR, in vitro and shares similar recognition sites as ScbR. However the effect on antibiotic production is much less dramatic than that of ScbR [19, 21]. Therefore ScbR still plays a key role in the S. coelicolor butanolide system involved in the regulation of the antibiotics Act and Red, and of the cpk secondary metabolite gene cluster (reviewed in ). We identified a variant ScbR with only one amino acid exchange in S. coelicolor M600 that is impaired in its DNA binding abilityandalters the expression of the pathway-specific regulators of two antibiotic biosynthetic gene clusters. This demonstrates that the γ-butyrolactone receptor, ScbR, plays a key role in the SCB regulatory cascade and in determining the onset of the expression of the antibiotic regulatory genes.This variant was only found in two Streptomyces coelicolor strainswhich most likely arose in laboratory conditions. To understand how this variant was selected twice may shed light on the evolutionary diversity of signalling receptor molecules.
Availability of supporting data
The data sets supporting the results of this article are included within the article and its additional files.
Bacterial strains, plasmids and cosmids
Strains and vectors used in this study are listed in Table 1 and Additional file 5. Streptomyces was manipulated as described previously . Escherichia coli was grown and transformed according to .
For culturing E. coli, liquid LB  or LB agar supplemented with appropriate antibiotics was used. For genomic DNA isolation Streptomyces was grown in liquid YEME/TSB (1:1) medium as described . MS medium  was used to harvest spores according to . To determine the viable spore concentration, dilution series of spore suspensions were plated on MS or DNA medium (DNagar)  and the number of colony forming units was determined. DNAgar supplemented with 325 mM (final conc.) L-Glutamic acid monosodium salt (Glu-DNAgar)  was used for determination of secondary metabolite production. For liquid Streptomyces cultures, strains were cultivated using SMM as previously described [9, 19]. Interspecific conjugation was done as described previously .
PCR and DNA sequencing
Amplification of DNA by PCR  was done with Taq polymerase (Fermentas), ProofStart polymerase (Qiagen) or the Expand High Fidelity DNA System (Roche). DNA sequence analysis was carried out by Sequence Laboratories, Göttingen, Germany.
DNA manipulation, plasmid transformation and intergeneric transfer
2D gel electrophoresis and MALDI-TOF mass spectrometry
Protein extracts were prepared from typically 25 ml culture samples according to  and mycelial pellets were stored at -80 °C until use.To prepare total protein extracts from spores, spores harvested from cultures grown on MS plates  and stored frozen in glycerol at −80 °C were thawed on ice, washed once with ice cold wash buffer , then transferred to a mortar submerged in liquid nitrogen together with an equal volume of washed glass beads (Sigma G-8893, 106 microns). The spores were then ground thoroughly under liquid nitrogen until an even colour and fine consistency (about 5 min), and the resulting frozen powder stored at −80 °C until use. Frozen aliquots were suspended in spore protein buffer (50 mM DTT, 4 mM Pefabloc SC protease inhibitor, 40 mM Tris pH 9.0, 1 mM EDTA, 1 mM EGTA and 2 % (w/v) SDS), sonicated briefly (Sanyo Soniprep 150; 2 x 5 second bursts at amplitude 7.5 microns), and then boiled for 10 min. After cooling, cell debris and glass beads were removed, the protein extract was cleaned up, and protein pellets were finally dissolved and stored frozen in aliquots at −80 °C until use as described in . Protein extracts from mycelia and spores were subjected to 2D gel electrophoresis as detailed in . The strip used for the separation was an 18 cm pH 5.5-6.7 IPG strip (Amersham Biosciences). Gels were stained with Sypro Ruby (Bio Rad) according to the manufacturer’s instructions, and scanned using the Perkin-Elmer ProXPRESS proteomic imaging system using excitation and emission wavelengths of 480 nm and 630 nm, respectively.
Protein spots of interest were excised from stained gels using the Investigator ProPic robot from Genomic Solutions, and identified by tryptic or chymotryptic digestion and MALDI-TOF mass spectrometry using a Micromass Q-TOF 2 mass spectrometer as previously described . Identification of proteins from peptide mass fingerprint data was performed according to .
Overexpression and purification of ScbRM145 for the generation of ScbR antibodies
The scbRM145 coding sequence was amplified by PCR from the cosmid SCAH10  using primers MalE-ScbR1 and MalE-ScbR2 (Additional file 2). The PCR product was gel-purified and ligated to pDRIVE (Qiagen), yielding pDRIVE-ScbR. This plasmid was digested with Bam HI and Hind III and the fragment corresponding to scbRM145 was ligated to the digested Bam HI/Hind III vector pTST101  to allow the translational fusion of scbRM145 with malE, leading to pTE88. The sequence of scbRM145 and the translational fusion were confirmed by DNA sequencing.
E. coli JM101 was transformed with pTE88. LB with 50 μg ampicillin ml-1 was inoculated to 1/100 volume with the overnight pre-culture and cells were grown at 37 °C until OD600 reached 0.5. L-rhamnose (0.2 % (w/v) final concentration) was added for induction. After a further 2 h of incubation the induced cells were harvested and washed twice with chilled Column Buffer (CB) (20 mMTris-HCl, 200 mM NaCl, 1 mM EDTA), resuspended in chilled CB and disrupted using a French-Press. The soluble fraction containing MalE-ScbRM145 was aliquoted and frozen at -70 °C until use. The MalE-ScbRM145 was further purified by affinity chromatography with amylose resin (New England Biolabs) using a Bio-Logic FPLC system (Bio-Rad). After elution with CB supplemented with 10 mM maltose, positive fractions (0.5-5 mg ml-1) detected by UV absorbance at 280 nm and shown to contain MalE-ScbRM145 (66.4 kDa) by SDS-PAGE were pooled. ScbRM145 was cleaved from MalE by the specific protease Factor Xa (10 μg ml-1 final concentration, New England Biolabs). Complete cleavage was determined by SDS-PAGE and cleavage was stopped by adding 2x Protease Inhibitor Cocktail (Roche). ScbRM145 (23.8 kDa) was further purified to homogeneity by affinity chromatography using a heparin column (Amersham Biosciences) coupled to the Bio-Logic FPLC system (Bio-Rad). ScbRM145 was eluted using a continuous salt gradient (0.2-2 M NaCl in CB). Positive fractions were checked on SDS-PAGE for presence and purity of ScbRM145 (Figure 9). The purified protein (0.8 mg) was used to generate antibodies in rabbits (Eurogentec S.A., Belgium).
SDS-PAGE and Western analysis
Cell-free extracts (CE) or purified ScbR were resolved by SDS-PAGE (12 % (w/v) resolving SDS-polyacrylamide gels) according to Laemmli’s procedure . Following electrophoresis, resolved bands were visualized by Coomassie brilliant blue staining. For Western analysis, proteins separated on SDS-PAGE gels were transferred to a nitrocellulose membrane by immersion or semi-dry blotting. Immunodetection of ScbR was carried out by using rabbit antiserum raised against ScbRM145 (this study) and horseradish peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad) as a secondary antibody with Roche’s CSP-Star (Figure 11B and Figure 9B) or NBT/BCIP (Figure 7B) as a substrate. In the former case, Super RX Medical X-ray Film (NIF100) (Fuji film) and a Lumi-Imager F1 (Roche) (Figure 11B) or a Konica QX-150U Medical Film Processor (Figure 9B) were used for detection.
Construction of the ScbRM600 expression plasmid and expression of both forms of ScbR in E. coli
A scbRM600 expression vector, pTE58, was constructed as described in detail in Additional file 6A, B. Plasmid pTE58 and the scbRM145 expression construct pIJ6120  contain the two forms of scbR with its own promoter region cloned behind the lacZ promoter in a pIJ2925 backbone. Expression constructs pTE58 and pIJ6120 were partially sequenced and differ only by the natural point mutation in scbRM600 (this study). E. coli JM101 was transformed with pTE58 and pIJ6120 for heterologous expression of ScbRM600 and ScbRM145 and CE was used for Western hybridisation analysis and gel retardation assays.
Cell-free extract preparation
For E. coli cell-free extract (CE), 10 ml LB overnight cultures of E. coli JM101 harbouring pIJ2925, pIJ6120 and pTE58 were inoculated at a 1/100 concentration in 50 ml LB without glucose. Cultures were incubated at 37 °C for 2.5 h or until OD600 0.7-0.8 and induced with 1 mM (final concentration) IPTG. After 3 h of further incubation cells were harvested and washed twice with ice cold disruption buffer (50 mM TrisHCl pH 7.9, 1 mM EDTA pH 8.0, 1 mM DTT, 1x (final conc.) complete EDTA-free protease inhibitor (Roche)) before being resuspended in 400 μl disruption buffer. For the E. coli CE used as positive control in Figure 7 the disruption buffer contained 20% (v/v; final conc.) glycerol. Cells of 100 μl aliquots were collected by centrifugation, the supernatant was removed completely and the cell pellet was frozen at −80 °C. To prepare CE, cells were resuspended in 150 or 200 μl disruption buffer and were disrupted by sonication. The cell lysate was clarified by centrifugation. Total protein concentration of the supernatant was determined using the BCA Protein Assay kit (Pierce) (for Figure 10 and Figure 9B) or a NanoDrop spectrophotometer (Thermo Fisher Scientific) (for Figure 7 and Figure 11). The freshly prepared CE was used immediately (Figure 10 and Figure 9B (100 μg total CE protein used), and Figure 7 (50 μg)). For Figure 11, the CE (130 μg total protein) was frozen and thawed up to three times at -20 °C (15 min) and 37 °C (5 min) before being applied to gel retardation assays and Western hybridisation analysis.
For S. coelicolor CE, cells from 25 ml samples of individual 60 ml SMM liquid cultures were collected at different phases of growth (Table 2, GC 1). Fresh CE was prepared with all cells obtained as described for E. coli using 100, 150 or 200 μl disruption buffer with glycerol. 500 μg total CE protein was used for Western analysis and gel retardation assays shown in Figure 8.
Gel retardation analysis
Gel retardation experiments were carried out as described previously  using the Roche DIG Gel Shift Kit (Roche cat No. 1635352). From a genomic DNA isolate of S. coelicolor M145, a 177 bp PCR fragment containing the ScbR binding site in the promoter region of scbR was amplified using primers ETS6 and ETS10 and then was DIG-labelled according to the manufacturer’s manual. For each sample approximately 0.23 ng (Figure 11A) and 1.8 ng (Figure 10) were used. For the results shown in Figure 8A, primer ETS10 was replaced by ETS10_DIG(5’) with digoxygenin linked to the 5’-end of the primer to obtain a labelled probe directly from PCR of which 5 ng was used in each sample (all primers are listed in Additional file 2). In some cases, 8 or 63 ng of chemically synthesised S. coelicolor γy-butyrolactone SCB1 was added to the mixture prior to incubation (Figure 10). For Figure 10, a Super RX Medical X-ray Film (NIF100) (Fuji film) and a Konica QX-150U Medical Film Processor were used for detection. Pictures for Figure 8A and Figure 11A were obtained with the Lumi-Imager F1 (Roche) and the Luminescent Image analyzer LAS-4000 (Fuji film), respectively.
Complementation of a S. coelicolor M145ΔscbR mutant (M752) with ScbRM145 and ScbRM600 by chromosomal replacement
scbRM145and scbRM600 complementation vectors were constructed as described in detail in Additional file 7A, B, C, D, E. Resulting plasmids pTE212 and pTE214 contain a 2.4 kb fragment of scbRM600 and scbRM145 and its flanking regions, respectively, in the conjugative, non-integrative vector pKC1132  which is non-replicating in S. coelicolor. The 2.4 kb inserts were sequenced and differ only by the natural point mutation in scbRM600 (this study) and an additional silent point mutation, c636t, in scbRM145 of pTE214 with no effect on the amino acid sequence of ScbRM145. pTE212 and pTE214 were transferred into S. coelicolor M752 by conjugation via E. coli ET12567/pUZ8002. Single- and double-crossover mutants were selected as described in , but using DNAgar for non-selective growth, yielding strains LW33 and LW34 in which the truncated scbRM145 region of the M145ΔscbRM145 mutant M752 was replaced by scbRM600 and scbRM145, respectively, in a M145 chromosomal background. Presence of full-length scbR genes at the right chromosomal location was confirmed by PCR using primers ETseq3 and ETS7 and Southern analysis  using a PCR-generated 484 bp probe (primers scbArt1 and scbArt2 labelled with a DIG DNA labelling kit (Roche) binding to a 2.37 kb DNA fragment of Nco I digested chromosomal DNA in the presence of full-length scbR (Figure 4A,B). With the in-frame deletion in scbRM145 in M752, an Nco I restriction site disappears and the probe binds to a 3.2 kb DNA fragment. The two variants of scbR in LW33 and LW34 were confirmed by specific PCR using primers RCseq31 and scbR-M145_c358 or scbR-M600_c358a (Figure 4C) and by DNA sequence analysis of the full-length scbR PCR product shown in Figure 4C (data not shown). All primers are listed in Additional file 2.
Reverse transcription and quantitative RT-PCR
RNA was isolated as previously described  from LW33 and LW34 grown in duplicate in liquid SMM at different times of growth. cDNA synthesis and quantitative RT-PCR was conducted as reported in .Three technical replicates per gene and time point were done and hrdB was used as endogenous control. All primers used for the qRT experiments are listed in Additional file 2. The averaged data is shown in Additional file 4A and the original study data are available as Additional file 8, data for growth curve 2 are shown in Figure 7.
Detection of γ-butyrolactone production in liquid S. coelicolor cultures
S. coelicolor LW33 and LW34 were grown in liquid SMM at 30 °C. At four time points (Table 2, GC 2), γ-butyrolactones were extracted from the culture supernatant as described in  and detected by the kanamycin bioassay .109 spores per plate of the indicator strain were plated out for confluent lawns on DNAgar plates containing 5 μg kanamycin ml-1. Each 5 μl of the γ-butyrolactones extracts, as well as 125 ng of the γ-butyrolactone SCB1 as positive control and the solvent methanol as negative control were spotted in the middle of the plates. After incubation for 3 days at 30 °C growth of the indictor strain was determined; pictures were taken from the bottom (Figure 6).
Determination of secondary metabolite production
4 x 107 spores per plate of S. coelicolor were streaked out for a 2.5 x 2.5 cm square on Glu-DNAgar, and pictures were taken from the bottom at different phases of growth to determine production of pigmented secondary metabolites (Figure 5). Antibiotic production in liquid cultures was determined as described previously .
Champness W: Actinomycete development, antibiotic production and phylogeny: questions and challanges. Prokaryotic Development. Edited by: Brun YV, Skimkets LJ. 2000, ASM Press, Washington, DC, USA, 11-31.
Miyadoh S: Research on antibiotic screening in Japan over the ILastdecade: A producing microorganism approach. Actinomycetologica. 1993, 7: 100-106. 10.3209/saj.7_100.
Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA: Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature. 2002, 417: 141-147. 10.1038/417141a.
Weaver D, Karoonuthaisiri N, Tsai HH, Huang CH, Ho ML, Gai S, Patel KG, Huang J, Cohen SN, Hopwood DA, Chen CW, Kao CM: Genome plasticity in Streptomyces: identification of 1 Mb TIRs in the S. coelicolor A3(2) chromosome. Mol Microbiol. 2004, 51: 1535-1550. 10.1111/j.1365-2958.2003.03920.x.
Takano E: Gamma-butyrolactones: Streptomyces signalling molecules regulating antibiotic production and differentiation. CurrOpin Microbiol. 2006, 9: 287-294.
Horinouchi S, Beppu T: Regulation of secondary metabolism and cell differentiation in Streptomyces: A-factor as a microbial hormone and the AfsR protein as a component of a two-component regulatory system. Gene. 1992, 115: 167-172. 10.1016/0378-1119(92)90555-4.
Horinouchi S: A microbial hormone, A-factor, as a master switch for morphological differentiation and secondary metabolism inStreptomyces griseus. Front Biosci. 2002, 7: d2045-d2057. 10.2741/horinouc.
Takano E, Nihira T, Hara Y, Jones JJ, Gershater CJ, Yamada Y, Bibb M: Purification and structural determination of SCB1, a gamma-butyrolactone that elicits antibiotic production in Streptomyces coelicolor A3(2). J BiolChem. 2000, 275: 11010-11016.
Takano E, Chakraburtty R, Nihira T, Yamada Y, Bibb MJ: A complex role for the gamma-butyrolactone SCB1 in regulating antibiotic production in Streptomyces coelicolor A3(2). MolMicrobiol. 2001, 41: 1015-1028.
Takano E, Kinoshita H, Mersinias V, Bucca G, Hotchkiss G, Nihira T, Smith CP, Bibb M, Wohlleben W, Chater K: A bacterial hormone (the SCB1) directly controls the expression of a pathway-specific regulatory gene in the cryptic Type I polyketide biosynthetic gene cluster ofStreptomyces coelicolor. MolMicrobiol. 2005, 56: 465-479.
Pawlik K, Kotowska M, Chater KF, Kuczek K, Takano E: A cryptic Type I polyketide synthase (cpk) gene cluster inStreptomyces coelicolor A3(2). Arch Microbiol. 2007, 187: 87-99. 10.1007/s00203-006-0176-7.
Gottelt M, Kol S, Gomez-Escribano JP, Bibb M, Takano E: Deletion of a regulatory gene within the cpk gene cluster reveals novel antibacterial activity inStreptomyces coelicolor A3(2). Microbiology. 2010, 156: 2343-2353. 10.1099/mic.0.038281-0.
Ramos JL, Martinez-Bueno M, Molina-Henares AJ, Teran W, Watanabe K, Zhang X, Gallegos MT, Brennan R, Tobes R: The TetR family of transcriptional repressors. Microbiol Mol Biol Rev. 2005, 69: 326-356. 10.1128/MMBR.69.2.326-356.2005.
Natsume R, Ohnishi Y, Senda T, Horinouchi S: Crystal structure of a gamma-butyrolactoneautoregulator receptor protein inStreptomyces coelicolor A3(2). J MolBiol. 2004, 336: 409-419.
Finley EL, Dillon J, Crouch RK, Schey KL: Identification of tryptophan oxidation products in bovine alpha-crystallin. Protein Sci. 1998, 7: 2391-2397. 10.1002/pro.5560071116.
Sambrook J, Russell DW: Molecular cloning: a laboratory manual. 2001, Cold Spring Harbor Laboratory Press, New York
MacNeil DJ, Occi JL, Gewain KM, MacNeil T, Gibbons PH, Ruby CL, Danis SJ: Complex organization of the Streptomyces avermitilis genes encoding the avermectin polyketide synthase. Gene. 1992, 115: 119-125. 10.1016/0378-1119(92)90549-5.
Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA: Practical Streptomyces Genetics. 2000, John Innes Foundation, Norwich, United Kingdom
Yang YH, Song E, Kim JN, Lee BR, Kim EJ, Park SH, Kim WS, Park HY, Jeon JM, Rajesh T, Kim YG, Kim BG: Characterization of a new ScbR-like γ-butyrolactone binding regulator (SlbR) in Streptomyces coelicolor. ApplMicrobiol Biotechnol. 2012, 10.1007/s00253-011-3803-4.
Chakraburtty R, Bibb M: The ppGppsynthetase gene (relA) ofStreptomyces coelicolor A3(2) plays a conditional role in antibiotic production and morphological differentiation. J Bacteriol. 1997, 179: 5854-5861.
Hsiao NH, Nakayama S, Merlo ME, de Vries M, Bunet R, Kitani S, Nihira T, Takano E: Analysis of two additional signaling molecules inStreptomyces coelicolorand the development of a butyrolactone-specific reporter system. ChemBiol. 2009, 16: 951-960.
Sugiyama M, Onaka H, Nakagawa T, Horinouchi S: Site-directed mutagenesis of the A-factor receptor protein: Val-41 important for DNA-binding and Trp-119 important for ligand-binding. Gene. 1998, 222: 133-144. 10.1016/S0378-1119(98)00487-9.
Bibb MJ: Regulation of secondary metabolism in streptomycetes. CurrOpin Microbiol. 2005, 8: 208-215.
Lu Y, Wang W, Shu D, Zhang W, Chen L, Qin Z, Yang S, Jiang W: Characterization of a novel two-component regulatory system involved in the regulation of both actinorhodin and a type I polyketide in Streptomyces coelicolor. ApplMicrobiol Biotechnol. 2007, 77: 625-635. 10.1007/s00253-007-1184-5.
Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae AW, Hopwood DA, van Wezel GP: Feast or famine: the global regulator DasR links nutrient stress to antibiotic production byStreptomyces. EMBO Rep. 2008, 9: 670-675. 10.1038/embor.2008.83.
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H: Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring HarbSymp Quant Biol. 1986, 51 (Pt 1): 263-273.
Leblond P, Fischer G, Francou FX, Berger F, Guerineau M, Decaris B: The unstable region of Streptomyces ambofaciens includes 210 kb terminal inverted repeats flanking the extremities of the linear chromosomal DNA. MolMicrobiol. 1996, 19: 261-271.
Hesketh AR, Chandra G, Shaw AD, Rowland JJ, Kell DB, Bibb MJ, Chater KF: Primary and secondary metabolism, and post-translational protein modifications, as portrayed by proteomic analysis ofStreptomyces coelicolor. MolMicrobiol. 2002, 46: 917-932.
Redenbach M, Kieser HM, Denapaite D, Eichner A, Cullum J, Kinashi H, Hopwood DA: A set of ordered cosmids and a detailed genetic and physical map for the 8 MbStreptomyces coelicolor A3(2) chromosome. MolMicrobiol. 1996, 21: 77-96.
Motejadded H, Altenbuchner J: Construction of a dual-tag system for gene expression, protein affinity purification and fusion protein processing. BiotechnolLett. 2009, 31: 543-549.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.
Bierman M, Logan R, O'Brien K, Seno ET, Rao RN, Schoner BE: Plasmid cloning vectors for the conjugal transfer of DNA fromEscherichia colitoStreptomyces spp. Gene. 1992, 116: 43-49. 10.1016/0378-1119(92)90627-2.
Strauch E, Takano E, Baylis HA, Bibb MJ: The stringent response inStreptomyces coelicolor A3(2). MolMicrobiol. 1991, 5: 289-298.
We thank D. Weaver and C. M. Kao for the provision of numerous S. coelicolor strains. We thank Atze van der Pol for technical assistance. MG was funded by the EU FP6 programme ActinoGEN (Project No. FP6 – 5224), RB was funded by Deutsche Forschungsgemeinschaft (TA428/2-1) DFG-Forschergruppe 449 ‘Bacterial cell envelope’. ET was supported by a Rosalind Franklin Fellowship from the University of Groningen.
None of the authors have a competing interest.
MG, AH, RB, and PP conducted the experiments. AH and ET designed the experiments. MG, AH and ET analysed the results and wrote the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 3 : Transcriptional analysis of redD , actII -orf4, cpkO , scbA and scbR M145/M600 using qRT-PCR in GC 1. A. qRT-PCR analysis of the transcription of redD, actII-orf4, cpkO, scbA and scbRM145/M600 using cDNA synthesized from RNA isolated from liquid SMM cultures of S. coelicolor LW34 (scbRM145) and LW33 (scbRM600). Samples were taken at four time points (tp 1–4) during different phases of growth indicated with eT, mT, lT and S (e arly, m id, l ate t ransition, and s tationary phase). Gene expression is shown as fold-change relative to the LW34 time point 1 early transition phase sample. Error bars indicate the standard deviation (see data in Additional file 3, GC 1). B. Numerical data from of the original qRT-PCR results. (PDF 126 KB)
Additional file 4 : Transcriptional analysis of redD , actII -orf4, cpkO , scbA and scbR M145/M600 using qRT-PCR in GC 1. A. qRT-PCR analysis of the transcription of redD, actII-orf4, cpkO, scbA and scbRM145/M600 using cDNA synthesized from RNA isolated from liquid SMM cultures of S. coelicolor LW34 (scbRM145) and LW33 (scbRM600). Samples were taken at four time points (tp 1–4) during different phases of growth indicated with eT, mT, lT and S (e arly, m id, l ate t ransition, and s tationary phase). Gene expression is shown as fold-change relative to the LW34 time point 1 early transition phase sample. Error bars indicate the standard deviation (see data in Additional file 3, GC 1). B. Numerical data from of the original qRT-PCR results. (PDF 9 KB)
Additional file 6 : Construction of the ScbR M600 expression vector pTE58. From a genomic DNA isolate of S. coelicolor strain M600, a 931 bp PCR fragment containing the scbR M600 coding sequence and the scbR promoter region was amplified using primers ETS3 and ScbR2 (Additional file 2). The PCR product was gel-purified and ligated to pDRIVE (Qiagen), yielding pTE51 of which the insert contains not only the natural mutation c358a in scbRM600, but also additional mutations: a30g in scbA is located in the promoter region of scbR, and nucleotide change t587a in the coding sequence of scbR M600 , respectively. The point mutation t587a leads to an amino acid change, D196V, in ScbRM600 (data not shown). A 948 bp pTE51/Eco RI scbR M600 fragment was cloned into the pUC18 derivate pIJ2925 to gain pTE53 containing all three described mutations (A). A 844 bp pTE53/Pst I fragment containing the scbR promoter region and nucleotides 1-535 of the scbR M600 coding region was ligated into a 3103 bp pIJ6120/Pst I vector fragment  containing nucleotides 536–648 of the scbR M145 coding region, yielding pTE56. Partial sequence analysis of pTE56 revealed only the scbR promoter mutation a30g in scbA and the expected coding sequence mutation c358a of scbR M600 . A 851 bp pTE56/Sac II fragment containing nucleotides 54–304 of scbR M600 was cloned into a 3047 bp pIJ6120/Sac II vector fragment containing the scbR promoter region and nucleotides 1–53 and 305–648 of the scbR M145 coding sequence, yielding pTE58 with scbR M600 and the scbR promoter region without additional undesired mutations in the same orientation as the IPTG-inducible E. colilacZ promoter (B). The scbR M145 expression construct pIJ6120  and pTE58 differ only by the natural mutation, c358a, in scbR M600 and were used for the heterologous expression of ScbRM145 and ScbRM600 in E. coli. Linear DNA fragments are named and a scale is given with indicated base pair (bp) units. Plasmids are named and represented by black circles. Genes are indicated by dark arrows and labelled with gene names. For incomplete genes the missing part is indicated by an apostrophe at the beginning or the end of the gene name. Antibiotic resistance genes are abbreviated with “amp” for ampicillin and “apra” for apramycin. “lacZ’” denotes for the LacZ α-peptide coding sequence. The position of the described mutations is indicated by labelled grey boxes on the scales and in the plasmid maps; relevant restriction sites are shown with enzyme names. Thick black lines with arrows indicate ligation events; big black arrows with enzyme names indicate corresponding restriction steps. (PDF 55 KB)
Additional file 7 : Construction of the complementation vectors pTE212 and pTE214. From genomic DNA isolates of S. coelicolor strains M145 and M600, a 2406 bp PCR fragment containing the scbRM145/M600 coding sequence and flanking regions was amplified using primers BamRCseq31enh and BamETseq1 (Additional file 2). PCR products were gel-purified and ligated to pGEM-T EASY (Promega), yielding pTE63 harbouring scbRM145 (A), and pTE64 (B) and pTE203 (C) harbouring scbRM600. The inserts of the plasmids were sequenced and pTE63 was found to contain mutations in scbRM145 (silent mutation c636t) and scbA (c308t leading to A103V). pTE64 contains a mutation in scbA (t77c leading to M26T), and pTE203 in scbB (c644t leading to A215V). Two 1405 bp pTE203/Pst I fragments were introduced by tandem integration into a 4016 bp pTE64/Pst I vector fragment to give pTE211, which is pGEM-T EASY with a 2394 bp Bam HI scbR M600 fragment without any additional mutations and an additional 1.4 kb Bam HI fragment. The 2394 bp pTE211/Bam HI fragment was cloned into pKC1132 to give pTE212 (D). A 1269 bp pTE63/Nco I fragment containing the silent mutation c636t in scbRM145 was cloned into a 4152 bp pTE211/Nco I vector fragment to give pTE213, which is pGEM-T EASY with a 2394 bp Bam HI scbR M145 fragment with only the silent mutation. The 2394 bp pTE213/Bam HI fragment was cloned into pKC1132 to give pTE214 (E). Linear DNA fragments are named and a scale is given with indicated base pair (bp) units. Plasmids are named and represented by black circles. Genes are indicated by dark arrows and labelled with gene names. For incomplete genes the missing part is indicated by an apostrophe at the beginning or the end of the gene name. The ampicillin antibiotic resistance gene is abbreviated with “amp”. The position of the described mutations is indicated by labelled grey boxes on the scales and in the plasmid maps; relevant restriction sites are shown with enzyme names. Thick black lines with arrows indicate ligation events; big black arrows with enzyme names indicate corresponding restriction steps. (PDF 301 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Gottelt, M., Hesketh, A., Bunet, R. et al. Characterisation of a natural variant of the γ-butyrolactone signalling receptor. BMC Res Notes 5, 379 (2012). https://doi.org/10.1186/1756-0500-5-379
- Gamma-butyrolactone receptor
- Gene regulation
- Antibiotic production